STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate to severe plaque psoriasis (PsO).STELARA is a fully human monoclonal antibody that selectively inhibits both interleukin (IL)-12 and IL-23, two cytokines thought to play an important role in tempering the overactive inflammatory response in several autoimmune diseases. STELARA is administered as a subcutaneous injection dosed four times per year after two starter doses for the treatment of pediatric patients six years of age and older with active PsA.“We know active pediatric psoriatic arthritis is a challenging inflammatory disease given its rarity and that symptoms, such as swollen joints and skin lesions, can vary significantly in presentation and severity,” said Terence Rooney, M.D., Ph.D., Vice President, Rheumatology and Maternal Fetal Disease Area, Janssen Research & Development, LLC. “With this pediatric approval of STELARA, we’re please...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
More News: Allergy | Allergy & Immunology | Arthritis | Autoimmune Disease | Babies | Babies Heart Conditions | Back Pain | Biotechnology | Brain | Brain Cancers | Breast Needle Aspiration | Breastfed | Bronchitis | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer Vaccines | Cardiology | Cardiovascular | Child Development | Children | Chronic Pain | Clinical Trials | Complementary Medicine | Cough | Disability | ENT & OMF | Food and Drug Administration (FDA) | Gastric (Stomach) Cancer | Genetics | Headache | Health Management | Heart | Herbs | Hospitals | Hypertension | Infectious Diseases | Inflammatory Bowel Disease | Insurance | Learning | Legislation | Marketing | Migraine | Milk | Neurology | Neuroscience | Nurses | Nursing | Pain | Pediatrics | Pharmaceuticals | Pregnancy | Profits and Losses | Psoriasis | Psoriatic Arthritis | Pulmonary Hypertension | Rare Diseases | Respiratory Medicine | Rheumatology | Science | Shingles | Shingles (Herpes Zoster) Vaccine | Skin | Skin Cancer | Sore Throat | Stelara | Study | Training | Tuberculosis | Tuberculosis (BCG) Vaccine | Ulcerative Colitis | Universities & Medical Training | Urinary Tract Infections | USA Health | Vaccines | Vitamins | Weight Loss